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Targeting fibrin in neurodegeneration
Deposition of fibrin in the brain and central nervous system occurs after injury or disease. This process unmasks a conserved cryptic epitope of fibrin that activates microglia; blocking this interaction can limit inflammation and neurotoxicity. roland martin T he clotting factor fibrin has a crucial role in blood coagulation. In this issue of Nature Immunology, Akassoglou and colleagues define a novel, specific role for fibrin in neurodegeneration 1 , for which important unmet medical needs exist in neurodegenerative and neuroinflammatory diseases such as Alzheimer's disease (AD) and multiple sclerosis (MS). Only symptomatic therapies are available for AD, and although MS can be treated with several immunomodulatory drugs, there is no remedy for the processes that drive nervecell damage, demyelination and clinical disability at its later stages, most notably radical-mediated stress 2 . Akassoglou and colleagues provide an elegant approach 1 that could lead to an urgently needed diseasemodifying therapy for both AD and MS 2 . The solution of the Akassoglou group and collaborators derives from a long interest in delineating how factors of the coagulation system contribute to a range of pathologies in the brain 2 . Blood clotting involves a series of well-orchestrated cellular and molecular steps that lead to temporal closure of a ruptured vessel and, starting from the contact of blood components with the injured vessel endothelium, changes in platelets and activation of the so-called 'extrinsic pathway' of the coagulation cascade. The last refers to the activation of several enzymes beginning with prothrombin, which is produced in the liver and is activated to thrombin by tissue factor. The subsequent intermediate steps lead to activation of coagulation factor X and then cleavage of the plasma protein fibrinogen to fibrin. The final common pathway results in closure of the damaged vessel by a polymerized fibrin clot.
The physiological functions of coagulation products include not only clotting but also trapping bacteria, direct antimicrobial effects, tissue remodeling and activation of the innate immune system [3] [4] [5] . These functions have received less attention overall. However, attention has been focused on another facet of the coagulation system, by the work of Akassoglou and others [5] [6] [7] . It was already observed several decades ago that fibrin deposition frequently occurs in the brain tissue of patients suffering from neurodegenerative and neuroinflammatory conditions such as AD and MS 6, 7 , but it also occurs in the experimental model of the latter: experimental autoimmune encephalomyelitis (EAE) 8 . The damaging role of fibrin(ogen) leakage in these conditions is underscored by the tight relationship between tissue fibrin and the clinical severity of EAE, the worsening of EAE when the gene encoding tissue plasminogen activator is deleted, and several other studies. Published studies over three decades ago showed that fibrin deposition can be targeted by a synthetic inhibitor of a plasminogen activator 9 .
It is now clear that the vascular system and brain engage in intense crosstalk 4, 5 . Beyond supplying blood and oxygen, cerebrovascular interactions are involved in maintaining endothelial-cell homeostasis, synaptic activity and neurogenesis in the adult organism, among other activities. Vessel damage, on the other hand, is involved in a host of pathologies ranging from bacterial meningitis to glioblastoma and AD. Whenever blood components leak into brain tissue, fibrin deposition then interacts, through receptorligand interactions and signaling steps involving kinases of the MAPK family and the transcription factor NF-κ B, with resident microglia and invading immune cells. Immune cell-derived cytokines such as TNF enhance fibrin formation and coagulation It shows that fibrin interacts via a cryptic epitope, fibrin γ 377-395 (which is exposed only after fibrin polymerization), with the CD11b I-domain of the complement receptor CR3 of microglia and macrophages and activates these innate immune cells (Fig. 1) . The authors reason that a monoclonal antibody (mAb) that binds to that cryptic epitope, but not the γ 400-411 site of fibrin (which mediates fibrin polymerization), should affect activation of the innate immune system but not coagulation. By screening mAbs for differential binding to γ 377-395 , but not the γ 400-411 epitope or another cryptic epitope, they identify mAb 5B8, which fulfils these criteria and binds with high affinity to the γ 377-395 site only. Subsequent transcriptomics experiments demonstrate that binding of fibrin to CR3 results in the upregulation of various genes encoding proinflammatory molecules, including the gene (Ncf4) encoding an important component of the NADPH oxidase (Nox2) complex, which has been linked to stroke and neurodegenerative diseases 10 . mAb 5B8 inhibits microglial activation and the NADPH oxidase pathway and prevents the release of reactive oxygen species. The potential neuroprotective effects are confirmed in co-cultures of fibrinactivated macrophages and neurons, in which 5B8 reduces the damage and loss of neurons. Those data are confirmed by analysis of 5B8 in three EAE models. 5B8 diminishes clinical signs and inhibits the accumulation of microglia and infiltration of macrophages in the spinal cord but does not affect peripheral adaptive immune responses.
Finally, Akassoglou and colleagues report the therapeutic potential of 5B8 in the5XFAD mouse model of AD 1 , in which AD-mutant forms of human amyloid precursor protein and presenilin are overexpressed in neurons. Deposition of fibrin in the brain of 5XFAD mice progressively accumulates from 3 months of age onward. Interestingly, 5B8 administered systemically reaches the brain and sites of plaque formation and reduces both microglia activation and the loss of cholinergic neurons, a hallmark of AD. Transcriptome analysis of the brain cortex of 5B8-treated 5XFAD mice demonstrates that 5B8 'preferentially' suppresses genes encoding molecules in five immunological pathways, most notably a hub of genes encoding components of the complement pathway: Tyrobp (also known as Dap12), C4b and C1q. Tyrobp encodes a co-receptor of CD11b and TREM2, another molecule that has been linked to AD 11 . What are the possible implications of the observations noted above? In MS, selective targeting of oxidative stress and the so-called 'neurodegenerative aspects' by 5B8 seems to be very attractive, since there is no therapy for these yet. Similarly, in AD, not only are genes encoding complement factors among the major risk genes 12 , but fibrin deposition and activation of the innate immune system at the sites of amyloid plaques are also considered important contributors to the progressive loss of nerve cells. So far, only the symptoms of AD can be treated by improvement of cholinergic nerve function, and while many compounds are in development, several have failed already and none directly targets the fibrinmediated activation of the immune system. The findings that 5B8 penetrates the bloodbrain-barrier, does not affect blood clotting and leaves other pathways for activation of the innate immune system and adaptive immunity seemingly intact while inhibiting a core pathological mechanism of MS, AD and other (neuro)inflammatory conditions such as stroke and rheumatoid arthritis indicate that it could be a very interesting and novel approach with which to treat these diseases. Due to the many differences between rodents and humans, such as differences in immunological function 13 , a note of caution is warranted, and the data should be validated in human systems. Furthermore, interactions of a fibrin γ -chain peptide truncated at position 399 have been shown to inhibit T cell activation 14 and, on the other hand, fibrin aids in the host defense against bacteria via both innate mechanisms and T cell-mediated mechanisms 15 . Targeting a specific site of fibrin that separates different functions of this pleiotropic mediator therefore holds great promise, but the effects of 5B8 could be even broader than indicated by this study of Akassoglou and colleagues 1 
